Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Επικοινωνία Submitted by Στέργιος Πολύζος on Τρί, 11/12/2019 - 09:43
